Harmony Biosciences Holdings, Inc.

HRMY Healthcare Biotechnology

Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.

Revenue
+12.3%
EPS
−6.24%
Free cash flow
−29.4%
Total debt
−11.5%

Quarter to September 2026, against a year earlier

33.04 0.57 +1.76%
Market cap
$1.9B
P/E
10.7×
Fwd P/E
9.9×
Dividend yield
—
F-score
5/9
Altman Z
5.23
Beneish M
−2.99
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Revenue
989.36 959.90 899.11 868.45

+8 more TTM periods

Gross Profit
732.42 723.99 688.25 670.11
Operating Income
219.36 230.65 189.52 208.47
EBT
232.96 241.20 197.57 215.06
Income after Tax
178.60 181.27 145.62 158.69
Net Income Common
178.60 181.27 145.62 158.69
EPS (Diluted)
3.02 3.08 2.48 2.71
Shares (Diluted, Weighted)
58.94 58.70 58.62 58.55
Gross Margin
74.03% 75.42% 76.55% 77.16%
EBIT Margin
22.17% 24.03% 21.08% 24.00%
Net Profit Margin
18.05% 18.88% 16.20% 18.27%
Free Cash Flow Margin
32.65% 36.99% 38.03% 40.06%
EBITDA
243.66 255.35 214.19 232.93
EBIT
219.36 230.65 189.52 208.47

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 6 Nov 2026